Under the terms of the agreement, HitGen will receive upfront payment and will be eligible for certain milestone payments.
SPARC is an international pharmaceutical company engaged in research and development of drugs and delivery systems.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.
